论文部分内容阅读
106例由纤维胃镜诊断的消化性溃疡住院病人,其中75例给痢特灵治疗,31例给与胃舒平作为对照组,治疗两周后复查胃镜以观察疗效。治疗组溃疡愈合56例(74.67％),溃疡缩小17例(22.67％),无变化2例(2.66％)。对照组溃疡愈合22例(70.97％),溃疡缩小6例(19.35％),无变化3例(9.68％)。两组的近期疗效无明显差异(P>0.6)。 73例进行了2～4年随访观察,痢特灵治疗组52例。其中4例(7.69％)复发,对照组21例其中7例(33.33％)复发。两组的复发病例数有明显差异(P<0.02)。 痢特灵的远期疗效比对照组为好,痢特灵的作用机制有待研究。
106 cases of peptic ulcer inpatients diagnosed by fiber endoscopy, of which 75 cases were treated with furazolidone, 31 cases were treated with Weishuping as control group, and the gastroscopy was performed two weeks later to observe the curative effect. In the treatment group, 56 cases (74.67%) had ulcer healing, 17 cases (22.67%) had ulcer reduction, and 2 cases (2.66%) had no change. In the control group, ulcer healed in 22 cases (70.97%), ulcer in 6 cases (19.35%) and no change in 3 cases (9.68%). No significant difference between the two groups in the short term efficacy (P> 0.6). 73 cases were followed up for 2 to 4 years, 52 cases were treated with furazolidone. Of these, 4 (7.69%) relapsed and 21 (33.33%) had relapse in the control group. There were significant differences between the two groups (P <0.02). The long-term efficacy of furazolidone was better than that of the control group, and the mechanism of action of furazolidone remains to be studied.